Population Pharmacokinetics of Ponatinib in Healthy Adult Volunteers and Patients With Hematologic Malignancies and Model-Informed Dose Selection for Pediatric Development
Michael J Hanley, Paul M Diderichsen, Narayana Narasimhan, Shouryadeep Srivastava, Neeraj Gupta, Karthik Venkatakrishnan, Michael J Hanley, Paul M Diderichsen, Narayana Narasimhan, Shouryadeep Srivastava, Neeraj Gupta, Karthik Venkatakrishnan
Abstract
The BCR-ABL1 inhibitor ponatinib is approved for the treatment of adults with chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia, including those with the T315I mutation. We report a population pharmacokinetic model-based analysis for ponatinib and its application to inform dose selection for pediatric development. Plasma concentration-time data were collected from 260 participants (86 healthy volunteers; 174 patients with hematologic malignancies) enrolled across 7 clinical trials. Data were analyzed using nonlinear mixed-effects modeling. Ponatinib pharmacokinetics were described by a 2-compartment model with first-order elimination from the central compartment. The final model included body weight and age as covariates on the apparent central volume of distribution; however, exposure variability explained by these covariates was small compared with overall variability in the population. None of the covariates evaluated, including sex, age (19-85 years), race, body weight (40.7-152.0 kg), total bilirubin (0.1-3.16 mg/dL), alanine aminotransferase (6-188 U/L), albumin (23.0-52.5 g/L), and creatinine clearance (≥28 mL/min) had clinically meaningful effects on apparent oral clearance. Simulations based on the final model predicted that daily doses of 15 to 45 mg result in steady-state average concentrations that are in the pharmacological range for BCR-ABL1 inhibition and approximate or exceed concentrations associated with suppression of T315I mutant clones. The final model was adapted using allometric scaling to inform dose selection for pediatric development. Clinicaltrials.gov identifier: NCT00660920; NCT01667133; NCT01650805.
Keywords: BCR-ABL; Philadelphia chromosome; acute lymphoblastic leukemia; chronic myeloid leukemia; pediatric; pharmacokinetics; ponatinib; tyrosine kinase inhibitors.
Conflict of interest statement
M.H. is an employee of Takeda Pharmaceutical Company Limited. P.D. is an employee of Certara and consultant to Takeda Pharmaceutical Company Limited. N.N. is a previous employee of ARIAD Pharmaceuticals, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. S.S. is a previous employee of Takeda Pharmaceutical Company Limited. N.G. is an employee of Takeda Pharmaceutical Company Limited. K.V. is a previous employee of Takeda Pharmaceutical Company Limited.
© 2021 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.
Figures
References
- O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan‐BCR‐ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation‐based resistance. Cancer Cell. 2009;16(5):401‐412.
- Deininger MW, Hodgson JG, Shah NP, et al. Compound mutations in BCR‐ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP‐CML patients. Blood. 2016;127(6):703‐712.
- Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872‐884.
- Iclusig [package insert]. Cambridge, MA: Takeda Pharmaceutical Company Limited; 2020.
- Cortes JE, Kim DW, Pinilla‐Ibarz J, et al. A phase 2 trial of ponatinib in Philadelphia chromosome‐positive leukemias. N Engl J Med. 2013;369(19):1783‐1796.
- Cortes JE, Kim DW, Pinilla‐Ibarz J, et al. Ponatinib efficacy and safety in Philadelphia chromosome−positive leukemia: final 5‐year results of the phase 2 PACE trial. Blood. 2018;132(4):393‐404.
- YE Ye, Woodward CN, Narasimhan NI. Absorption, metabolism, and excretion of [(14)C] ponatinib after a single oral dose in humans. Cancer Chemother Pharmacol. 2017;79(3):507‐518.
- Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D. Effects of food on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharm Ther. 2013;38(6):440‐444.
- Narasimhan NI, Dorer DJ, Niland K, Haluska F, Sonnichsen D. Effects of ketoconazole on the pharmacokinetics of ponatinib in healthy subjects. J Clin Pharmacol. 2013;53(9):974‐981.
- Narasimhan NI, Dorer DJ, Davis J, Turner CD, Sonnichsen D. Evaluation of the effect of multiple doses of lansoprazole on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Drug Investig. 2014;34(10):723‐729.
- Narasimhan NI, Dorer DJ, Davis J, Turner CD, Sonnichsen D. Evaluation of the effect of multiple doses of rifampin on the pharmacokinetics and safety of ponatinib in healthy subjects. Clin Pharmacol Drug Develop. 2015;4(5):354‐360.
- Tojo A, Kyo T, Yamamoto K, et al. Ponatinib in Japanese patients with Philadelphia chromosome‐positive leukemia, a phase 1/2 study. Int J Hematol. 2017;106(3):385‐397.
- Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome‐positive leukemias. N Engl J Med. 2012;367(22):2075‐2088.
- Lipton JH, Chuah C, Guerci‐Bresler A, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open‐label, phase 3 trial. Lancet Oncol. 2016;17(5):612‐621.
- Bauer RJ. NONMEM Users Guide: Introduction to NONMEM 7.3.0. Gaithersburg, MD: ICON Development Solutions; 2015.
- R Development Core Team . R: A Language and Environment for Statistical Computing. Vienna, Austria; 2013.
- Savic RM, Karlsson MO. Importance of shrinkage in empirical Bayes estimates for diagnostics: problems and solutions. AAPS J. 2009;11(3):558‐569.
- Wahlby U, Jonsson EN, Karlsson MO. Comparison of stepwise covariate model building strategies in population pharmacokinetic‐pharmacodynamic analysis. AAPS Pharm Sci. 2002;4(4):E27.
- Centers for Disease Control and Prevention, National Center for Health Statistics . Selected percentiles and LMS parameters. . Accessed November 3, 2021.
- Gleevec [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2020.
- Savic RM, Jonker DM, Kerbusch T, Karlsson MO. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J Pharmacokinet Pharmacodyn. 2007;34(5):711‐726.
- Huang WS, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3‐[2‐(imidazo[1,2‐b]pyridazin‐3‐yl)ethynyl]‐4‐methyl‐N‐{4‐[(4‐methylpiperazin‐1‐yl)‐methyl]‐3‐(trifluoromethyl)phenyl} benzamide (AP24534), a potent, orally active pan‐inhibitor of breakpoint cluster region‐abelson (BCR‐ABL) kinase including the T315I gatekeeper mutant. J Med Chem. 2010;53(12):4701‐4719.
- Cortes JE, Lomaia E, Turkina A, et al. Interim analysis (IA) of OPTIC: A dose‐ranging study of three ponatinib (PON) starting doses [abstract]. J Clin Oncol. 2020;38(15 suppl):7502.
- de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37(6):485‐505.
- Boberg M, Vrana M, Mehrotra A, et al. Age‐dependent absolute abundance of hepatic carboxylesterases (CES1 and CES2) by LC‐MS/MS proteomics: application to PBPK modeling of oseltamivir in vivo pharmacokinetics in infants. Drug Metab Dispos. 2017;45(2):216‐223.
- Upreti VV, Wahlstrom JL. Meta‐analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling. J Clin Pharmacol. 2016;56(3):266‐283.
- Salem F, Johnson TN, Abduljalil K, Tucker GT, Rostami‐Hodjegan A. A re‐evaluation and validation of ontogeny functions for cytochrome P450 1A2 and 3A4 based on in vivo data. Clin Pharmacokinet. 2014;53(7):625‐636.
Source: PubMed